Teva Pharmaceutical's pipeline, including Duvakitug and multiple biosimilars, offers significant growth prospects, with several key Phase 3 ... The graphic below highlights the impact of Sanofi's ...

Really excited to talk to you today about the 2024 performance of Teva and the lookout for 2025 ... But TL1A acts as a key amplifying signal. It binds to a variety of different cells in the ...

Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries ... But TL1A acts as a key amplifying signal. It binds to a variety of different cells in ...

The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...

Pancreatic cancer, one of the most aggressive and lethal types of cancer, continues to present significant challenges in both its detection and treatment. The lack of early detection tools, coupled ...

(Continued from "Pharma news highlights ... Teva Pharmaceuticals has temporarily frozen plans to fire those workers while talks are held simultaneously with the government and key labor unions.

Appellate courts issued a variety of notable intellectual property (IP) cases in 2024, including cases touching on Orange Book ...

Portfolio Receipts Highlights ... quarter of 2025. The key developments related to Royalty Pharma’s royalty interests are discussed below based on disclosures from the marketers of the products.

Businesses must align with key regulations and be compliant ... Major investors in the Indian pharmaceutical sector include AstraZeneca, Dr. Reddy’s, GSK, Divi’s, Zydus, Novartis, Pfizer, Sun Pharma, ...

In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva ...